GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (OTCPK:RSLS) » Definitions » Asset Turnover

Reshape Lifesciences (Reshape Lifesciences) Asset Turnover : 0.21 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Reshape Lifesciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Reshape Lifesciences's Revenue for the three months ended in Dec. 2023 was $1.98 Mil. Reshape Lifesciences's Total Assets for the quarter that ended in Dec. 2023 was $9.25 Mil. Therefore, Reshape Lifesciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. Reshape Lifesciences's annualized ROE % for the quarter that ended in Dec. 2023 was -139.38%. It is also linked to ROA % through Du Pont Formula. Reshape Lifesciences's annualized ROA % for the quarter that ended in Dec. 2023 was -73.47%.


Reshape Lifesciences Asset Turnover Historical Data

The historical data trend for Reshape Lifesciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Asset Turnover Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.30 0.30 0.35 0.80

Reshape Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.17 0.16 0.22 0.21

Competitive Comparison of Reshape Lifesciences's Asset Turnover

For the Medical Devices subindustry, Reshape Lifesciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Asset Turnover falls into.



Reshape Lifesciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Reshape Lifesciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=8.678/( (11.142+10.663)/ 2 )
=8.678/10.9025
=0.80

Reshape Lifesciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=1.982/( (7.827+10.663)/ 2 )
=1.982/9.245
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Reshape Lifesciences  (OTCPK:RSLS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Reshape Lifesciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-6.792/4.873
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.792 / 7.928)*(7.928 / 9.245)*(9.245/ 4.873)
=Net Margin %*Asset Turnover*Equity Multiplier
=-85.67 %*0.8575*1.8972
=ROA %*Equity Multiplier
=-73.47 %*1.8972
=-139.38 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Reshape Lifesciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-6.792/9.245
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-6.792 / 7.928)*(7.928 / 9.245)
=Net Margin %*Asset Turnover
=-85.67 %*0.8575
=-73.47 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Reshape Lifesciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (Reshape Lifesciences) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Barton P. Bandy officer: President and CEO 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Dan W Gladney director, officer: Chairman, President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Scott P Youngstrom officer: CFO and SVP, Finance 2800 PATTON ROAD ST. PAUL MN 55113
Joseph Patrick Healey 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Healthcor Partners Ii, L.p. 10 percent owner 152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Michael Y Mashaal director 309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452
Healthcor Partners Fund Ii, L.p. 10 percent owner CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Jeffrey C Lightcap 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019
Healthcor Partners Management Gp, Llc 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019

Reshape Lifesciences (Reshape Lifesciences) Headlines

From GuruFocus

ReShape Lifesciences to Present at the Q4 Investor Summit

By Value_Insider Value_Insider 11-02-2022